Authors
Loading...
Randomized trial demonstrates improved EGFR-targeted protein degradation in tumor sites, indicating enhanced therapeutic potential.
Ma et al. (2026) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: